Hong Kong Geriatrics Society and Hong Kong Urological Association consensus on personalised management of male lower urinary tract symptoms in the era of multiple co-morbidities and polypharmacy

Hong Kong Med J. 2021 Apr;27(2):127-139. doi: 10.12809/hkmj209049.ABSTRACTLower urinary tract symptoms (LUTS) are common complaints of adult men. Benign prostatic hyperplasia (BPH) represents the most common underlying cause. As the incidence of BPH increases with age, and pharmacological treatment is a major part of the disease's management, the majority of patients with LUTS are managed by primary care practitioners. There are circumstances in which specialist care by urologists or geriatricians is required, such as failure of medical treatment, adverse effects from medical treatment, or complications from BPH. Referral choices can be confusing to patients and even practitioners in different specialties under such circumstances. There is currently no local consensus about the diagnosis, medical management, or referral mechanism of patients with BPH. A workgroup was formed by members of The Hong Kong Geriatrics Society (HKGS) and the Hong Kong Urological Association (HKUA) to review evidence for the diagnosis and medical treatment of LUTS. A consensus was reached by HKGS and HKUA on an algorithm for the flow of male LUTS care and the use of uroselective alpha blockers, antimuscarinics, beta-3 adrenoceptor agonists, and 5α-reductase inhibitors in the primary care setting. This consensus by HKGS and HKUA provides a new management paradigm of male LUTS.PMID:33879628 | DOI:10.12809/hkmj209049
Source: Hong Kong Med J - Category: General Medicine Authors: Source Type: research

Related Links:

To analyze the safety of mirabegron add-on therapy in men with overactive bladder symptoms concurrently receiving tamsulosin for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
AbstractPurposeTo present our experience of the patterns of revascularisation of the prostate and efficacy of repeat prostate artery embolisation (rPAE) in patients with recurrence of lower urinary tract symptoms.Materials and MethodsWe retrospectively analysed 12 patients who underwent rPAE at a single centre between November 2015 and March 2020. The patients had their intraprocedural angiography and cone beam CT images as well as their pre-procedural CT retrospectively reviewed to establish the patterns of revascularisation. Clinical follow-up occurred at a minimum of 3  months.Results11/12 patients (91.6%) had sign...
Source: CardioVascular and Interventional Radiology - Category: Radiology Source Type: research
This study aimed to examine the effects of AQP5 on estrogen-induced EMT in the prostate. METHODS: Normal prostate (NP) tissue samples without any histopathological changes and BPH tissue samples with pathologically confirmed hyperplasia were obtained. An EMT cell model was subsequently established by adding estradiol (E2) to RWPE-1 cells, after which AQP5 knockdown was performed. Tissue morphological and immunohistochemical features were examined using hematoxylin-eosin and immunohistochemical staining. Western blot analysis was performed to determine the expression of AQPs, estrogen receptors, and EMT-related protein...
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
As Prostate Artery Embolization (PAE) for treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) becomes more commonly performed, operator knowledge of the adverse events is essential to inform patient selection, patient preparation, and post-procedural management. The aim of this article is to the discuss the incidence, presentation, and management of the PAE adverse effects.
Source: Techniques in Vascular and Interventional Radiology - Category: Radiology Authors: Source Type: research
AbstractPurposeTo investigate the safety and effectiveness of superselective prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).MethodsSixty-five patients diagnosed with BPH in Fujian Provincial Hospital between December 2014 and July 2019 were included. Patients with ineffective drug treatment after 6  months, who refused surgery, or who were unsuitable for surgery were included. We observed postoperative complications, followed up at 1, 3, and 6 months, compared clinical symptoms, and monitored changes in prostate-specific antigen (PSA) and prostatic volume (PV) before and a...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Prostate artery embolization (PAE) is a minimally invasive treatment option for benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS) (1-7). Operators require a detailed understanding of the prostate arterial anatomy (origins and collaterals) to ensure technical and clinical success with minimal complications (8). Because of the high variability in pelvic vascular anatomy, several classification systems have been developed to better identify and characterize prostate arteries.
Source: Techniques in Vascular and Interventional Radiology - Category: Radiology Authors: Source Type: research
In conclusion, this study provides novel evidence that febuxostat experimentally attenuates testosterone-induced BPH in rats, at least in part by inhibiting iNOS/COX-2 and VEGF/TGF-β pathways. PMID: 33031799 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) occur in 50% of men over the age of 50 years, and prevalence increases with age. Patients traditionally have been managed with a combination of medical and surgical treatments. Transurethral resection of the prostate (TURP) is the gold standard for surgical treatment of BPH. Within the past decade, prostate artery embolization (PAE) has emerged as a minimally invasive alternative for the treatment of BPH, urinary retention, and hematuria of prostatic origin.
Source: Techniques in Vascular and Interventional Radiology - Category: Radiology Authors: Source Type: research
Medically refractory benign prostatic hyperplasia (BPH) induced lower urinary tract symptoms (LUTS) is an extremely prevalent issue in older men. The current gold standard therapy transurethral resection of the prostate (TURP) does produce urologic improvements but is also associated with higher than desired morbidity. This has led to the need to develop new minimally invasive means to treat this disease; prostate artery embolization (PAE) has emerged as one minimally invasive treatment option for these patients.
Source: Techniques in Vascular and Interventional Radiology - Category: Radiology Authors: Source Type: research
Hematuria of prostatic origin has multiple etiologies including benign prostatic hyperplasia (BPH), iatrogenic urological trauma, prostate cancer, and radiation therapy. Hematuria secondary to benign prostatic hyperplasia (BPH) can occur because of the increased vascularity of the primary gland, itself, or because of the vascular re-growth following a transurethral resection of the prostate. Prostatic hematuria usually resolves with conservative measures; however, refractory hematuria of prostatic origin (RHPO) may require hospitalization with treatment with blood transfusions, repeated indwelling urinary catheterization, ...
Source: Techniques in Vascular and Interventional Radiology - Category: Radiology Authors: Source Type: research
More News: Benign Prostatic Hyperplasia | General Medicine | Geriatrics | Hong Kong Health | Primary Care | Urology & Nephrology